Everand Logo

Welcome to Everand!

  • STAT

    Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

    Christi Shaw, an Eli Lilly executive, has been named the new head of Kite Pharma, which is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.
    by Matthew Herper Jul 11, 2019 2 minutes

    Christi Shaw, until Thursday morning the executive in charge of Eli Lilly’s drug division, will become the CEO of Kite Pharma, the unit of biotechnology giant Gilead that is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

    Shaw said she was inspired to take the job because that type of treatment, known as CAR-T, is what she wants to focus

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks